davidulmert (@davidulmert) header
davidulmert (@davidulmert) profile picture

Director, Preclinical Theranostics Program at UCLA. Parka monkey. Tweets are my own.

California, USA
Joined September 2014
We're proud to share Dr. Matthew Rettig received a VA Clinical Cancer Research Center grant to build a precision oncology hub for veterans in the Southwest, expanding access to clinical trials & advanced care for those who have sacrificed so much. bit.ly/3LUgVo8
1
6
89
Big Cancer Breakthrough UCLA Scientists Develop Antibody That Hunts and Destroys Aggressive Cancers UCLA scientists have developed a powerful new cancer fighting antibody, DUNP19, that can both detect and destroy some of the deadliest, most treatment resistant tumors like osteosarcoma and glioblastoma. This breakthrough "radiotheranostic" approach uses the same antibody for imaging and treatment - mild radiation to spot tumors, and stronger doses to wipe them out. DUNP19 hunts down a protein called LRRC15, found on aggressive cancer cells but rarely in healthy tissue, allowing ultra precise targeting with minimal side effects. In mice, this therapy stopped tumor growth, extended survival, and reprogrammed the tumor environment to make it vulnerable to immune attack, supercharging the effects of immunotherapy. The first human clinical trial for patients with metastatic osteosarcoma is set to launch later this year. 👀 UCLA researchers say this could mark a major leap forward in fighting cancers once thought untreatable.
38
164
21
1,004
60,030
A team of researchers led by @davidulmert has identified a promising new treatment strategy that can detect, kill & reprogram aggressive, treatment-resistant tumors like osteosarcomas & glioblastoma. bit.ly/3VZychI
3
5
358
Demonstrating DUNP19, a monoclonal antibody targeting LRRC15, as a highly specific radio-theranostic modality for the non-invasive detection and mitigation of pro-tumorigenic mechanisms & immunotherapy resistance. @UCLA #STTT #OpenAccess: doi.org/10.1038/s41392-025-0…
1
1
128
davidulmert retweeted
Human kallikrein 2 (encoded by the KLK2 gene; KLK2) is a novel target expressed in prostate cancer cells. KLK2 pipeline — from radiopharmaceuticals to bispecifics and CAR-T —underscores an exciting era where KLK2-based modalities may transform prostate cancer diagnosis and treatment. Abs: 5017 - Phase 1 study results of JNJ-78278343 (Pasritamig) in mCRPC (at @ASCO 2025) show Pasritamig as a first-in-class T-cell-redirecting BsAb binding KLK2. Get the latest #ASCO25 updates as they happen: t.ly/7TCD6 #LARVOL #ProstateCancer #BsAb #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights | @TiansterZhang | @TapiaJC1 | @dralvaropinto | @PGrivasMDPhD | @DrRanaMcKay | @MattGalsky | @SuyogCancer
12
4
21
11,631
🗣️Prostate Rapid Oral Abstract #ASCO25 👉Abst5017: Dr #CapucineBaldini presenting #Pasritamig in mCRPC 🔑 KEY TAKE AWAYS - #Pasritamig well tolerated (<10% G1 CRS @ RP2D) with promising antitumor activity. - Proof of concept for #KLK2 as a target amenable to T-cell redirection. - Unmet need for targeted #TcellTherapy safe to administer in an outpatient setting w/ meaningful benefit in mCRPC. 👥@neerajaiims @Silke_Gillessen @APCCC_Lugano @Prof_Nick_James @CParkMD @ChrisSweens1 @AtishChoudhury @TDorffOnc @xiaoweimd @CaPsurvivorship @drenriquegrande @bavilima @DRBakaloudiMD @nataliagandur @bergsa83 @OncoAlert @OncBrothers @urotoday @Uromigos
2
8
15
2,132
🔎Phase 1 results of JNJ-78278343 (pasritamig) in mCRPC? A first in class bispecific T-cell engager targeting human kallikrein2... a specific prostate antigen ✅Remarkable safety profile differentiated from prior T-cell engages with/ low rates of TRAE and infrequent CRS (8.9%, all grade 1 and did not require tocilizumab) ✅Achieved durable disease control and rPFS that compare to historical data in heavily pretreated mCRPC @ASCO @oncoalert @Oncolive @TargetedOnc @OncoReporte @Urotoday #ASCO25 #genitourinarycancer @WinshipAtEmory
5
5
773
Oral presentation here @ASCO #ASCO25 describing a new target and mechanism in Prostate Cancer. #MyCompany
2
4
310
davidulmert retweeted
A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2, for #mCRPC. Presentation by @morr316 @MSKCancerCenter. #ASCO24 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4aMr8d5
1
8
15
1,630
There have been calls by some Muslim leaders to boycott Jewish products in solidarity with Palestine! We would like to help the Muslim world in their boycott, and as such, here is a list of things that need to be avoided...
2,059
5,997
997
28,508
5,216,250
Den talande tystnaden är öronbedövande. Den antisemitism som blottat sig i samhället är skrämmande. Fler behöver träda fram och ställa sig upp och visa sitt stöd för vår judiska minoritet som är under bred attack i Sverige och i omvärlden! Det är oacceptabelt! #NeverAgain
172
776
33
4,367
157,544
EBRT increased AR pathway activity + [89Zr]11B6 uptake in PC bearing mice + [89Zr]11B6 uptake correlated with #hK2 protein levels. Further evaluation provided, [89Zr]11B6-PET imaging could be a potential monitoring tool for EBRT (or other treatments targeting AR axis/hK2)
2
5
383
Exciting news! Our article on utilizing hK2-PET (89Zr-11B6) to assess AR-activity in PCa post external beam irradiation is now published in MCR as the cover story! Big thanks to the editorial team and associate editor @adscheid33 for their support: https://teapaw.org/t.co/eoTyt3Uyog
1
7
576